Baidu
map

Cell:大规模癌症基因组研究(TCGA)可能重新定义肿瘤分型

2014-08-11 佚名 生物通

来自美国加州的消息,癌症基因组图谱研究(Cancer Genome Atlas,TCGA)项目组公布了一项癌症基因组最大规模研究结果,研究人员在多个基因组技术平台上分析了超过3500个肿瘤,从中发现了一种能区分癌症的新方法。这一同领域最大规模的研究成果公布在8月7日的Cell杂志上,领导这一研究的是加州大学圣克鲁兹分校Buck研究所Christopher Benz和 Christina Yau。2

来自美国加州的消息,癌症基因组图谱研究(Cancer Genome Atlas,TCGA)项目组公布了一项癌症基因组最大规模研究结果,研究人员在多个基因组技术平台上分析了超过3500个肿瘤,从中发现了一种能区分癌症的新方法。

这一同领域最大规模的研究成果公布在8月7日的Cell杂志上,领导这一研究的是加州大学圣克鲁兹分校Buck研究所Christopher Benz和 Christina Yau。

2007年,美国国立卫生研究院NIH宣布进行为期两年、总值340万美元的癌症基因组图谱研究计划(Cancer Genome Atlas pilot program),这一计划目标是“测试一种大规模、系统性分析癌细胞基因组变化的方法的可行性”,为检测、治疗、预防癌症提供基因组信息。

在过去的几年里,这一项目陆续获得了一些研究成果,而在最新这项研究中,研究人员采用6种不同的TCGA“平台技术(platform technologies)”,分析了12种不同肿瘤类型样品的DNA,RNA和蛋白,希望能从中发现不同类型的肿瘤如何相互区分。

研究结果表明相对于癌症起源的组织类型,如乳房肾脏、膀胱等,相同癌症起源的细胞类型具有更多分子和遗传上的相似性。


文章的通讯作者Benz指出,我们组织中大部分是由许多不同类型的上皮细胞和非上皮细胞组成,“这项颠覆性的基因组研究不仅挑战了基于组织类型的现有癌症分类系统,而且还提供了能用于进一步研究的大量新数据来源,以及能用于区分每种新描述癌症类型的分子特征整体列表,”Benz说,“比如说膀胱癌能重新被分成几种不同的癌症类型,每一种都具有不同的临床表征,这就有助于解释对看似相同的癌症类型进行相同的全身疗法治疗,为什么患者往往反应截然不同”。

这一研究组发现在十个癌症患者中至少有一个能通过这种新系统分类到不同的癌症类型中,而且Benz认为如果他们下一轮进行更多的样品,和肿瘤类型的分析,将会有更多的肿瘤需要重新分类,他预计下一轮将进行超过20种不同肿瘤类型的分析。

“考虑到这种多平台类型基因组分析的潜力,我们还只是分析了冰山的一角。未来可能还有多达30%或 50%的癌症需要被重新归类”。

在这项研究中,最引人注目的发现就是膀胱癌和乳腺癌方面的成果,至少有三个不同亚型的膀胱癌需要重新分类:一种是无法与肺腺癌区分开来的亚型,一种是与起源自头部,颈部和肺部的鳞状上皮细胞癌很相似的亚型。

这项研究也指出和证实了乳腺癌类型中已知的差异,而且还揭示出了新的令人惊讶的发现——基底样乳腺癌实际上是一类新癌症类型。

基底样乳腺癌(Basal-like breast cancers)通常称为三阴性乳腺癌(triple-negative breast cancer),是一种特别具有侵袭性,并致命的癌症。“即使这些基底样癌症出现在乳腺中,但在分子水平上它们与卵巢癌和鳞状上皮细胞起源的癌症更为相似,”Yau说。

Benz认为这一研究将能被用于临床试验设计,尤其是希望能通过肿瘤基因组重分类,寻找新的治疗方法的患者,“虽然需要后续的研究来验证,并完善这一新提出的癌症分类系统,但是这项研究最终将能为个性化癌症医疗时代的到来,奠定基础生物学基础。”

TCGA项目相关研究:

The Cancer Genome Atlas Research Network; Analysis Working Group: Dana-Farber Cancer Institute; Institute for Systems Biology; University of Southern California; Memorial Sloan Kettering Cancer Center; BC Cancer Agency; Comprehensive molecular characterization of gastric adenocarcinoma.Nature. 2014 Jul 23. doi: 10.1038/nature13480. [Epub ahead of print]

Cancer Genome Atlas Research Network.Comprehensive molecular profiling of lung adenocarcinoma.Nature. 2014 Jul 31;511(7511):543-50. doi: 10.1038/nature13385. Epub 2014 Jul 9.


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1949289, encodeId=ea96194928965, content=<a href='/topic/show?id=5ed95833172' target=_blank style='color:#2F92EE;'>#新定义#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58331, encryptionId=5ed95833172, topicName=新定义)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Mon Oct 13 14:27:00 CST 2014, time=2014-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043289, encodeId=67c32043289ce, content=<a href='/topic/show?id=13304400293' target=_blank style='color:#2F92EE;'>#大规模#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44002, encryptionId=13304400293, topicName=大规模)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fce464, createdName=ylz8403, createdTime=Mon Feb 09 04:27:00 CST 2015, time=2015-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2066988, encodeId=800c2066988fa, content=<a href='/topic/show?id=2ec9e133569' target=_blank style='color:#2F92EE;'>#癌症基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71335, encryptionId=2ec9e133569, topicName=癌症基因)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Sun Apr 05 04:27:00 CST 2015, time=2015-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868879, encodeId=55b818688e92e, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Apr 11 23:27:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959124, encodeId=ed8b1959124af, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Jun 28 16:27:00 CST 2015, time=2015-06-28, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1949289, encodeId=ea96194928965, content=<a href='/topic/show?id=5ed95833172' target=_blank style='color:#2F92EE;'>#新定义#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58331, encryptionId=5ed95833172, topicName=新定义)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Mon Oct 13 14:27:00 CST 2014, time=2014-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043289, encodeId=67c32043289ce, content=<a href='/topic/show?id=13304400293' target=_blank style='color:#2F92EE;'>#大规模#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44002, encryptionId=13304400293, topicName=大规模)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fce464, createdName=ylz8403, createdTime=Mon Feb 09 04:27:00 CST 2015, time=2015-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2066988, encodeId=800c2066988fa, content=<a href='/topic/show?id=2ec9e133569' target=_blank style='color:#2F92EE;'>#癌症基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71335, encryptionId=2ec9e133569, topicName=癌症基因)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Sun Apr 05 04:27:00 CST 2015, time=2015-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868879, encodeId=55b818688e92e, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Apr 11 23:27:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959124, encodeId=ed8b1959124af, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Jun 28 16:27:00 CST 2015, time=2015-06-28, status=1, ipAttribution=)]
    2015-02-09 ylz8403
  3. [GetPortalCommentsPageByObjectIdResponse(id=1949289, encodeId=ea96194928965, content=<a href='/topic/show?id=5ed95833172' target=_blank style='color:#2F92EE;'>#新定义#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58331, encryptionId=5ed95833172, topicName=新定义)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Mon Oct 13 14:27:00 CST 2014, time=2014-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043289, encodeId=67c32043289ce, content=<a href='/topic/show?id=13304400293' target=_blank style='color:#2F92EE;'>#大规模#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44002, encryptionId=13304400293, topicName=大规模)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fce464, createdName=ylz8403, createdTime=Mon Feb 09 04:27:00 CST 2015, time=2015-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2066988, encodeId=800c2066988fa, content=<a href='/topic/show?id=2ec9e133569' target=_blank style='color:#2F92EE;'>#癌症基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71335, encryptionId=2ec9e133569, topicName=癌症基因)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Sun Apr 05 04:27:00 CST 2015, time=2015-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868879, encodeId=55b818688e92e, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Apr 11 23:27:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959124, encodeId=ed8b1959124af, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Jun 28 16:27:00 CST 2015, time=2015-06-28, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1949289, encodeId=ea96194928965, content=<a href='/topic/show?id=5ed95833172' target=_blank style='color:#2F92EE;'>#新定义#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58331, encryptionId=5ed95833172, topicName=新定义)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Mon Oct 13 14:27:00 CST 2014, time=2014-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043289, encodeId=67c32043289ce, content=<a href='/topic/show?id=13304400293' target=_blank style='color:#2F92EE;'>#大规模#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44002, encryptionId=13304400293, topicName=大规模)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fce464, createdName=ylz8403, createdTime=Mon Feb 09 04:27:00 CST 2015, time=2015-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2066988, encodeId=800c2066988fa, content=<a href='/topic/show?id=2ec9e133569' target=_blank style='color:#2F92EE;'>#癌症基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71335, encryptionId=2ec9e133569, topicName=癌症基因)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Sun Apr 05 04:27:00 CST 2015, time=2015-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868879, encodeId=55b818688e92e, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Apr 11 23:27:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959124, encodeId=ed8b1959124af, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Jun 28 16:27:00 CST 2015, time=2015-06-28, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1949289, encodeId=ea96194928965, content=<a href='/topic/show?id=5ed95833172' target=_blank style='color:#2F92EE;'>#新定义#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58331, encryptionId=5ed95833172, topicName=新定义)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Mon Oct 13 14:27:00 CST 2014, time=2014-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043289, encodeId=67c32043289ce, content=<a href='/topic/show?id=13304400293' target=_blank style='color:#2F92EE;'>#大规模#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44002, encryptionId=13304400293, topicName=大规模)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fce464, createdName=ylz8403, createdTime=Mon Feb 09 04:27:00 CST 2015, time=2015-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2066988, encodeId=800c2066988fa, content=<a href='/topic/show?id=2ec9e133569' target=_blank style='color:#2F92EE;'>#癌症基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71335, encryptionId=2ec9e133569, topicName=癌症基因)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Sun Apr 05 04:27:00 CST 2015, time=2015-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868879, encodeId=55b818688e92e, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sat Apr 11 23:27:00 CST 2015, time=2015-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959124, encodeId=ed8b1959124af, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Jun 28 16:27:00 CST 2015, time=2015-06-28, status=1, ipAttribution=)]
    2015-06-28 维他命

相关资讯

Nature:肺腺癌基因组综合发现一些潜在的靶点

来自“癌症基因组图谱研究网络(The Cancer Genome Atlas Research Network)”的这篇报告发布了230个切除的、未处理过的肺腺癌样本的分子特征。对转录组、基因组、甲基化组和蛋白质组所做的综合分析识别出了高速度的体细胞突变、包括NF1, MET, ERBB2 and RIT1 在13%患者中有突变发生。RIT1 和MGA在内的显著突变的基因以及由体细胞基因组变化驱

Nature:基因组研究发现膀胱癌分子机制

     日前,来自癌症基因组图谱研究网络(The Cancer Genome Atlas Research Network, TCGA)的研究人员在《自然》杂志上报告称,他们确定了一种主要的膀胱癌形式的新潜在治疗靶点,其中包括疾病中遭到破坏的一些重要基因和信号通路。    此外,他们还发现,在分子水平上一些称作为膀胱上皮癌的膀胱癌亚型,与某些乳

Nature:詹启敏院士发现与食管鳞癌基因组中8个重要基因突变

   日前,英国《自然》杂志在线发表由中国医学科学院肿瘤医院分子肿瘤学国家重点实验室主任詹启敏院士团队与华大基因、汕头大学医学院等合作取得的一项科学成果。       研究人员通过高通量测序、比较基因组杂交芯片分析、生物学功能和临床验证研究,全面系统揭示了食管鳞癌的遗传突变背景,发现了与食管鳞癌发生发展进程和临 床预后相关

CSMO 2014:肿瘤基因组学研究进展及临床转化应用

在7月4日的第八届中国肿瘤内科大会上,南京医科大学的沈洪兵教授介绍了肿瘤基因组学研究进展及临床转化应用。 肿瘤基因组学 肿瘤基因组学是在人类基因组学的基础上,寻找癌相关基因组及遗传序列,筛选及检测肿瘤特异性或相关性表达,判断基因间相互关系,并比较个体之间基因差异,最终用于指导肿瘤发病机制研究及临床肿瘤个体化治疗。肿瘤基因组学的研究主要包括3方面的研究内容:①恶性肿瘤易患性的遗传背景。②遗传物质

Science:中国科学家领衔“破译”绵羊基因组

由中国科学家领衔的一个国际科研小组5日宣布,历经5年时间,他们完成了对绵羊基因组的测序、组装及分析工作。这项成果使人们对反刍动物生物学有了崭新认识。更重要的是,中国是绵羊和山羊饲养及羊肉消费大国,新研究将促进选育出更优秀的肉羊新品种。绵羊基因组的测序工作在2009年正式启动,其中中国科学院昆明动物研究所与华大基因联合测序一头母羊,而英国罗斯林研究所测序一头公羊,参考基因组序列在2012年对外正式发

新一代基因测序:整个人类基因组只需18分钟

近日有国外媒体透露,圣地亚哥一家创业公司EdicoGenome正在开发一种有望从根本上降低新一代测序(NGS)数据分析成本和时间的技术。“该技术非常有吸引力”,竟吸引来了Life Tech原CEO Gregory Lucier加入该公司1000万美元A轮融资的投资者行列。据了解,由EdicoGenome开发的Dynamic Read Analysis for Genomics (DRAGEN)生物

Baidu
map
Baidu
map
Baidu
map